{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:08:09Z","timestamp":1778544489712,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81400105"],"award-info":[{"award-number":["81400105"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81700104"],"award-info":[{"award-number":["81700104"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["30800487"],"award-info":[{"award-number":["30800487"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970147"],"award-info":[{"award-number":["81970147"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770170"],"award-info":[{"award-number":["81770170"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["2014A020212185"],"award-info":[{"award-number":["2014A020212185"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["2016A020215112"],"award-info":[{"award-number":["2016A020215112"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2017A030313601"],"award-info":[{"award-number":["2017A030313601"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010264","name":"Shanghai Maritime University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010112","name":"Nanfang Hospital","doi-asserted-by":"publisher","award":["LC2016ZD009\/2019CR012"],"award-info":[{"award-number":["LC2016ZD009\/2019CR012"]}],"id":[{"id":"10.13039\/501100010112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.biopha.2020.110390","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T19:05:40Z","timestamp":1592420740000},"page":"110390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells"],"prefix":"10.1016","volume":"129","author":[{"given":"Bailin","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaochan","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengyun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing Z.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qifa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongsheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2020.110390_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.biopha.2020.110390_bib0010","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.110390_bib0015","doi-asserted-by":"crossref","DOI":"10.1007\/s12185-020-02843-8","article-title":"Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and\/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line","author":"Sakurai","year":"2020","journal-title":"Int. J. Hematol."},{"issue":"5531","key":"10.1016\/j.biopha.2020.110390_bib0020","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.biopha.2020.110390_bib0025","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.biopha.2020.110390_bib0030","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/bjh.13103","article-title":"Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia","volume":"168","author":"Giona","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.biopha.2020.110390_bib0035","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00277-016-2820-x","article-title":"Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion","volume":"96","author":"Breccia","year":"2017","journal-title":"Ann. Hematol."},{"issue":"3","key":"10.1016\/j.biopha.2020.110390_bib0040","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/bloodadvances.2019000268","article-title":"Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia","volume":"4","author":"Chan","year":"2020","journal-title":"Blood Adv."},{"issue":"24","key":"10.1016\/j.biopha.2020.110390_bib0045","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.biopha.2020.110390_bib0050","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/leu.2015.196","article-title":"\u03b2-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"29","author":"Eiring","year":"2015","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.biopha.2020.110390_bib0055","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/leu.2017.87","article-title":"Combined inhibition of beta-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo","volume":"31","author":"Zhou","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.biopha.2020.110390_bib0060","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","article-title":"Loss of \u03b2-catenin impairs the renewal of normal and CML stem cells in vivo","volume":"12","author":"Zhao","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2020.110390_bib0065","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4103\/abr.abr_142_19","article-title":"Histone deacetylases and histone deacetylase inhibitors: molecular mechanisms of action in various cancers","volume":"8","author":"Sanaei","year":"2019","journal-title":"Adv. Biomed. Res."},{"issue":"4","key":"10.1016\/j.biopha.2020.110390_bib0070","doi-asserted-by":"crossref","DOI":"10.3390\/diseases7040057","article-title":"Histone deacetylases and their inhibitors in cancer epigenetics","volume":"7","author":"Hassell","year":"2019","journal-title":"Diseases"},{"issue":"10","key":"10.1016\/j.biopha.2020.110390_bib0075","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2020.110390_bib0080","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-016-0266-1","article-title":"A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed\/refractory peripheral T-cell lymphoma patients","volume":"9","author":"Pellegrini","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2020.110390_bib0085","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1158\/1078-0432.CCR-11-0234","article-title":"HDAC inhibitors potentiate the activity of the BCR\/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR\/ABL+ leukemia cells in vitro and in vivo","volume":"17","author":"Nguyen","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2020.110390_bib0090","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.biopha.2020.110390_bib0095","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2020.110390_bib0100","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"12","key":"10.1016\/j.biopha.2020.110390_bib0105","first-page":"7644","article-title":"A combination of low-dose decitabine and chidamide resulted in synergistic effects on the proliferation and apoptosis of human myeloid leukemia cell lines","volume":"11","author":"Xu","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.biopha.2020.110390_bib0110","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3389\/fonc.2019.01276","article-title":"Chidamide enhances the cytotoxicity of cytarabine and sorafenib in acute myeloid leukemia cells by modulating H3K9me3 and autophagy levels","volume":"9","author":"Huang","year":"2019","journal-title":"Front. Oncol."},{"issue":"15","key":"10.1016\/j.biopha.2020.110390_bib0115","first-page":"3603","article-title":"Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase","volume":"53","author":"Beran","year":"1993","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.biopha.2020.110390_bib0120","first-page":"5995","article-title":"Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR\/ABL-positive cell line","volume":"62","author":"Ricci","year":"2002","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.biopha.2020.110390_bib0125","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/sj.leu.2402608","article-title":"Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins","volume":"16","author":"Konopleva","year":"2002","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.biopha.2020.110390_bib0130","doi-asserted-by":"crossref","first-page":"951","DOI":"10.4161\/cbt.28931","article-title":"SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells","volume":"15","author":"Bu","year":"2014","journal-title":"Cancer Biol. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2020.110390_bib0135","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.18632\/oncotarget.3239","article-title":"Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response","volume":"6","author":"Mensah","year":"2015","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.biopha.2020.110390_bib0140","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-08-0721","article-title":"Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells","volume":"14","author":"Fiskus","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2020.110390_bib0145","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"29","key":"10.1016\/j.biopha.2020.110390_bib0150","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors","volume":"280","author":"Bali","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2020.110390_bib0155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/leu.2013.184","article-title":"Multifaceted roles of GSK-3 and Wnt\/beta-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention","volume":"28","author":"McCubrey","year":"2014","journal-title":"Leukemia"},{"issue":"46","key":"10.1016\/j.biopha.2020.110390_bib0160","doi-asserted-by":"crossref","first-page":"17967","DOI":"10.1073\/pnas.0808303105","article-title":"BCR-ABL-transformed GMP as myeloid leukemic stem cells","volume":"105","author":"Minami","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220305837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220305837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:11:49Z","timestamp":1778541109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332220305837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":32,"alternative-id":["S0753332220305837"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110390","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110390","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"110390"}}